Originally published Sept. 28.
By Turna Ray
In its third drug/diagnostic co-development deal announced in 14 months, GlaxoSmithKline has struck a partnership with OncoMethylome Sciences for the "potential use" of one of OncoMethylome's DNA methylation-specific PCR biomarkers to personalize a drug in its immunotherapy development program.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.